Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295318 | 0.97 | DPYD (0.54) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL1050748 | 0.83 | DPYD (0.47) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL16585678 | 0.80 | GPR84 (0.46) | DPYDMAPTALDH1A1ATAD2TSHR | |
| SCHEMBL1890981 | 0.79 | DPYD (0.50) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL887754 | 0.79 | DPYD (0.50) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL17553298 | 0.75 | DPYD (0.46) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL3485393 | 0.75 | DPYD (0.53) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL2001029 | 0.75 | DPYD (0.53) | DPYDGAAMAPTALDH1A1ATAD2 | |
| SCHEMBL16586721 | 0.74 | GPR84 (0.43) | DPYDMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL16586691 | 0.74 | GPR84 (0.43) | DPYDMAPTLMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101887-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125412-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4683927-A1 | ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS | Illumina, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025230760-A1 | REVERSIBLY TERMINATED NUCLEOTIDES WITH MODIFIED PHOSPHATE CHAINS, AND METHODS OF MAKING AND USING THE SAME | ILLUMINA, INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-2024196883-A1 | ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS | ILLUMINA, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240317793-A1 | NUCLEOSIDE TRIPHOSPHATES WITH MODIFIED PHOSPHATE CHAINS, AND METHODS OF SYNTHESIZING THE SAME | ILLUMINA, INC. (US) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125412-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | PNP, MTAP, SLC35B2 | DPYD 24/4885GAA 1715/4885MAPT 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.